durvalumab
astrazeneca
['durva', 'durvalumab']
 2022 updates:
after providing significant results in 1st line advanced #biliarytractcancer &amp; positive pros, #durvalumab showed consistent results across regional subgroups as well as no effect on its efficacy by the #hepatitis status. learn more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry